Life Sciences Litigation Risk Rises With AI Disputes

Biotech operators face a more offensive patent environment as new AI authorship issues complicate standard intellectual property claims.

Updated on Oct. 28, 2026 in Healthcare

Bold flat-color editorial illustration depicting a glass molecule structure over a geometric grid, symbolizing intellectual property litigation in science. — Life sciences companies are increasingly using offensive litigation to protect patent assets as AI authorship questions complicate industry intellectual property standards. AI Illustration. Upload story photo >

Live Poll

Do you believe companies should be more aggressive in pursuing patent litigation to protect their market share?

A new survey from Miller Johnson reveals that life sciences companies maintain an offensive posture in patent litigation at a rate of 17%, significantly higher than the 10% average across broader market sectors. These findings highlight intensifying competition and emerging disputes over AI-driven product development.

Why it matters

Pharmaceutical firms are aggressively utilizing litigation to defend market share and high profit margins, creating a more litigious environment for smaller peers. The early integration of AI in drug development is also forcing companies to navigate new intellectual property risks regarding human versus AI authorship.

Life sciences companies pursue an offensive patent posture at 17% vs. 10% for the broader market, while 74% of corporate counsel report frequent patent involvement. Additionally, private equity firms deployed $21.33 billion across 284 biotech deals in 2026.

The players

Miller Johnson

A law firm that provides legal counsel and publishes research on intellectual property litigation trends.

BioXconomy

A media platform focused on the business and economic developments of the life sciences industry.

The details

Life sciences firms are leveraging aggressive litigation strategies to protect high-margin products, a departure from the more reactive stances of general market companies. Larger entities are currently three times as likely to initiate offensive litigation than middle-market firms. Furthermore, in-house counsel are increasingly managing these costs by spreading litigation expenditures over longer timelines to maintain stable monthly budgets, which averaged $250,000 for those involved in active disputes.

Over the past 12 months, 74% of corporate counsel handled patent disputes.
In 2026, private equity firms completed 284 biotech investments.
October 2026 marked the discussion of survey results with BioXconomy.

Market Landscape

Current litigation trends are running headlong into the U.S. patent law requirement that only humans can be listed as inventors. This conflict is accelerating as life sciences firms integrate AI faster than other sectors, creating a new frontier for intellectual property disputes.

Operators in life sciences should prepare for higher litigation budgets and review AI-driven R&D workflows for potential patentability risks. Given the aggressive offensive posture of larger competitors, ensure internal IP documentation explicitly identifies the human contribution to all AI-assisted technical milestones.

The takeaway

The sharp divide between life sciences and other sectors in patent litigation signals a high-stakes environment where IP is a primary competitive weapon. Managers should track their internal AI development processes against current inventor requirements to avoid future challenges to their product pipelines.